Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: International Murex Technologies

This article was originally published in The Gray Sheet

Executive Summary

International Murex Technologies: Commences overseas launch of its second-generation enzyme immunoassay for serological genotyping of Hepatitis C (HCV). The test which identifies whether a patient is infected with HCV types 1-6, will be marketed to "leading diagnostic laboratories," Murex says. The firm notes that the "sale of this test is not currently affected by injunctions blocking Murex from manufacturing and selling its Anti-HCV test." Murex has been enjoined from making and selling HCV assays by a German court because the products infringe German and European patents held by Chiron ("The Gray Sheet" Jan. 2, In Brief)...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT005176

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel